# Louis Saint-Jacques

> Louis Saint-Jacques is a seed investor at AQC Capital backing Health Care. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [AQC Capital](https://shizune.co/investors/profile/anges-qu%C3%A9bec-capital)
- Location: Montréal, Canada
- Total investments: 3
- Last investment: Feb 2023
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/louissaintjacques/

Louis Saint-Jacques is a seed investor at AQC Capital in Montréal focused on Health Care and Audio. Louis Saint Jacques is the Partner/Associate at AQC Capital. He attended University of Quebec in Montreal.

## Contacts

5 contacts available for Louis Saint-Jacques: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/louis-saint-jacques?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 100% |
| Audio | 1 | 33% |
| Chemical | 1 | 33% |
| Hardware | 1 | 33% |
| Biopharma | 1 | 33% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AAVAA | AAVAAdevelops a bionic ear that helps reduce noise and acts as a hearing impairment correction device. | $1.5M | Seed | Feb 15, 2023 |  |
| Elkimia | Elkimia develops and research of sun protection products. They provide products that include research, development, and manufacturing. Their customers' inquiries are addressed through phone, email, and online applications. |  | Venture - Series Unknown | Aug 01, 2022 |  |
| Giiant Pharma | Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M | Seed | May 21, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 3 deals together
- [Amorchem](https://shizune.co/investors/profile/amorchem) — VC Fund, 1 deal together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 1 deal together
- [CQDM](https://shizune.co/investors/profile/cqdm) — VC Fund, 1 deal together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 1 deal together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 1 deal together

## About AQC Capital

VC Fund · Montréal, Canada

AQC Capital is an investment fund created to provide financial support to Anges Québec members. The fund is mainly sponsored by Investissement Québec to support angel investors who invest in innovative seed or start-up companies in Quebec. This joint effort by the angels and Investissement Québec has made more than $30 million available toentrepreneurs, allowing them to benefit from more substantial financial leverage in order to considerably increase the development of their business.

4 contacts available at AQC Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Kalthoum Bouacida | Vice President Investments | — |
| Louis Saint-Jacques | Partner/Associate | — |
| David Dufresne | Investment Partner | https://shizune.co/investors/profile/david-dufresne |
| Serge Beauchemin | Founder & Managing Partner | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Louis Saint-Jacques invest in?

Louis Saint-Jacques invests primarily in Health Care, Audio and Chemical startups, most often at Seed and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Louis Saint-Jacques?

Public channels for Louis Saint-Jacques include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Louis Saint-Jacques last invest?

The most recent investment recorded for Louis Saint-Jacques closed in Feb 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co